Novel CD19/CD22-CAR T-cell product overcomes one of the current roadblocks of CD19-CAR T-cell therapy (CART) for ALL. (A) Current roadblocks of CART include immune escape and limited persistence. (B) Novel CD19/CD22-CART product generated by cotransduction with optimized CARs: product contains T cells expressing both CARs (green) or one of the two CARs (blue or yellow). (C) Outcome of phase 1 clinical study. (D) Next steps. For additional details, see text. Figure created with BioRender.com.